SCM
RLMD icon

Sio Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Sio Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-235,600
Closed -$822K – 54
2022
Q4 		$822K Sell
235,600
-370,600
-61% -$3.25M 0.3% 34
2022
Q3 		$22.4M Buy
+606,200
New +$16.8M 7.13% 5

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sio Capital Management's RLMD Position: Q2 2026 in Review

Sio Capital Management increased its Relmada Therapeutics (RLMD) stake by 4% in Q2 2026, buying an estimated $269K and bringing the position to 1,003,562 shares worth $6.94M. The position accounts for 1.15% of the portfolio, ranked #30.

Sio Capital Management first reported a position in RLMD in Q4 2022 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Sio Capital Management held 1,003,562 shares of Relmada Therapeutics worth $6.94M as of Q2 2026.
  • Sio Capital Management bought 38,562 Relmada Therapeutics shares in Q2 2026, an estimated $269K.
  • Relmada Therapeutics made up 1.15% of Sio Capital Management's portfolio in Q2 2026, its #30 holding.
  • Sio Capital Management first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.